Alvotech sells US copies of 1 of the blockbuster drugs on this tracker and has 10 filed or in development. Those brands earned $77.5B in 2025. Of the 70 makers we follow, 3 are lined up to copy more of these drugs.
| Drug | Alvotech's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara SelarsdiBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 16 Apr 2024; launched 21 Feb 2025; interchangeable With Teva |
7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Drug | Alvotech's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Prolia AVT03Biosimilar · Amgen · US LOE 2025 | Filed with the FDA; in litigation, sued Nov 2025. FDA turned it down in Dec 2025 over factory issues only; back under review after the FDA cleared the factory in Jul 2026 With Dr. Reddy's |
7 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva AVT03Biosimilar · Amgen · US LOE 2025 | Filed with the FDA; in litigation, sued Nov 2025. FDA turned it down in Dec 2025 over factory issues only; back under review after the FDA cleared the factory in Jul 2026 With Dr. Reddy's |
6 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Simponi AVT05Biosimilar · Johnson & Johnson · US LOE 2026 | Filed with the FDA. FDA turned it down in Oct 2025 over factory issues only; resubmitted Jun 2026 With Teva |
0 on sale · 1 approvedof 1 other maker listed | $2.7B |
| Entyvio AVT16Biosimilar · Takeda · US LOE 2032 | Filed with the FDA; in litigation, sued Sep 2026. FDA decision expected Q1 2027 With Teva |
0 on sale · 0 approvedof 2 other makers listed | ≈$6.0B |
| Drug | Alvotech's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Xolair AVT23Biosimilar · Roche / Novartis · US LOE 2026 | Early development With Kashiv |
1 on sale · 0 approvedof 1 other maker listed | ≈$5.4B |
| Keytruda AVT32Biosimilar · Merck · US LOE 2028 | In clinical trials. US filing planned for 2028 With Dr. Reddy's |
0 on sale · 0 approvedof 9 other makers listed | $31.7B |
| Taltz AVT28Biosimilar · Eli Lilly · US LOE 2030 | Early development | 0 on sale · 0 approvedof 2 other makers listed | $3.6B |
| Imfinzi AVT34Biosimilar · AstraZeneca · US LOE 2031 | Early development | None listed | $6.1B |
| TremfyaBiosimilar · Johnson & Johnson · US LOE 2031 | Early development | 0 on sale · 0 approvedof 3 other makers listed | $5.2B |
| KesimptaBiosimilar · Novartis · US LOE 2031 | Early development. Europe partner: Advanz | None listed | $4.4B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Alvotech's own sales. See the launch tracker →
Each row is a copy Alvotech sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Alvotech's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Alvotech's sales; several makers usually share a market once copies launch.
About 30 biosimilars in development; four US applications awaiting FDA action (Oct 2026), across all products, not just the drugs tracked here.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: SEC company tickers; Alvotech 20-F 2025, Alvotech: FDA clears Reykjavik facility, 5 Oct 2026.